
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Edesa Biotech Inc (EDSA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.
Year Target Price $13
Year Target Price $13
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Under performing |
0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.74% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.40M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 1.55 - 5.59 | Updated Date 06/30/2025 |
52 Weeks Range 1.55 - 5.59 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.29% | Return on Equity (TTM) -58.78% |
Valuation
Trailing PE - | Forward PE 0.17 | Enterprise Value 13379036 | Price to Sales(TTM) 120477.93 |
Enterprise Value 13379036 | Price to Sales(TTM) 120477.93 | ||
Enterprise Value to Revenue 128525.38 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 7022680 | Shares Floating 3728761 |
Shares Outstanding 7022680 | Shares Floating 3728761 | ||
Percent Insiders 28.41 | Percent Institutions 43.53 |
Analyst Ratings
Rating 5 | Target Price 13 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Edesa Biotech Inc
Company Overview
History and Background
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative treatments for inflammatory and immune-related diseases with unmet medical needs. Founded in 2007, Edesa's initial focus was on dermatology, expanding later to include other areas. Key milestones include clinical trial advancements of their lead product candidates.
Core Business Areas
- Pharmaceutical Development: Edesa develops and tests pharmaceutical products through clinical trials, seeking regulatory approval and eventual commercialization. Their focus is on dermatological and other immune-related conditions.
Leadership and Structure
Dr. Par Nijhawan is the Chief Executive Officer. The company has a board of directors overseeing the strategic direction. Edesa operates with a relatively small team, outsourcing certain functions like manufacturing and clinical trial management.
Top Products and Market Share
Key Offerings
- EB05 (Phase 3 stage asset, anti-inflammatory sNDA candidate): EB05 is Edesa's main product candidate, an anti-inflammatory sNDA candidate currently in Phase 3 trials for moderate-to-severe chronic allergic contact dermatitis (ACD). Market share is currently 0% as it's not yet approved. Competitors include topical corticosteroids and calcineurin inhibitors like tacrolimus and pimecrolimus. This product revenue cannot be reported as it has not been approved yet.
- EB01 (Topical treatment): EB01 is an investigational product for the treatment of atopic dermatitis. There is no revenue from this product. Competitors include topical corticosteroids, calcineurin inhibitors and monoclonal antibodies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Key trends include personalized medicine, rising healthcare costs, and stringent regulatory requirements. Companies need strong pipelines and funding to succeed.
Positioning
Edesa is a small player focusing on niche markets within dermatology and other immune-related diseases. Its competitive advantage relies on developing novel therapies for unmet needs. They are focused on an anti-inflammatory medication for ACD.
Total Addressable Market (TAM)
The global atopic dermatitis market is expected to be worth around $18 billion. Edesa, with its investigational product EB01, is positioned to try to compete for a piece of this market. The allergic contact dermatitis (ACD) market TAM is harder to quantify as a standalone, but it is a significant part of the overall dermatology market, potentially worth billions.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical needs
- Experienced management team
- Promising clinical trial results
- Partnerships with research institutions
Weaknesses
- Limited financial resources
- Reliance on a few key products
- High risk of clinical trial failure
- Small market capitalization
Opportunities
- Potential for breakthrough therapies
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Government grants and funding
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expiration
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- VRX
- LEO
- BMY
Competitive Landscape
Edesa faces significant competition from larger, more established pharmaceutical companies. Edesa's advantage lies in developing novel therapies for niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as Edesa is a development-stage company. Growth is expected to occur if products are approved and commercialized.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its product candidates. Analyst projections are speculative and subject to change.
Recent Initiatives: Recent initiatives include advancing EB05 through Phase 3 clinical trials and seeking partnerships for further development and commercialization.
Summary
Edesa Biotech is a clinical-stage company focused on dermatology and immunology. The company has potential with its lead product EB05 progressing through trials. However, it faces substantial risks with limited resources and a dependence on positive clinical trial outcomes. Strong competition and regulatory hurdles add further challenges, requiring careful risk management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided may not be exhaustive, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edesa Biotech Inc
Exchange NASDAQ | Headquaters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.edesabiotech.com |
Full time employees 16 | Website https://www.edesabiotech.com |
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.